AXIN2 and esophageal cancer: In esophageal cancer, the 5-year survival rate of high expression of PRR11 was significantly lower than that of the low expression group, which may be related to the interaction of PRR11 with destructive complexes (APC, GSK-3β and AXIN2) to activate the Wnt/β-catenin pathway 14.